Establishments involved in cord blood collection

The Designated Individual (DI) at the licensed establishment is responsible for ensuring suitable practices take place under the authority of the Human Tissue Authority (HTA) licence. As procurement of cord blood is usually undertaken on Relevant Third Party Premises (RTPP) under a third party agreement (TPA), DIs must develop robust procedures to assure themselves that cord blood is appropriately procured, received, quarantined and risk assessed prior to acceptance into the establishment.

Background

The Q&S Regulations and associated HTA Directions require any person collecting cord blood to be acting under the authority of an HTA licence or a Third Party Agreement with an HTA-licensed establishment. The HTA Directions also require the procurer to be appropriately trained to the satisfaction of the DI to undertake the safe collection of the cord blood. The requirement for training of procurers is set down in paragraph 95 of the Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatments as implemented by Directions 001/2021.

Collection of cord blood by untrained personnel may increase the risk of physical harm to the donor (in this case, both the mother and child). Additionally, collection of cord blood by untrained personnel, or on unsuitable premises, increases the risk of contamination of the cord blood. Microbiological contamination could lead to the cells being disposed of prior to storage, which would therefore not be available for future use, or otherwise harm the recipient if contaminated cells are transplanted in the future.

The HTA uses its licensing framework as an assurance that suitable practices are being carried out by suitable people on suitable premises, under the supervision of a DI. Acting outside of this framework takes these assurances away from the HTA.

The HTA considers that unlawful procurement of cord blood (that is, procurement of cord blood on premises unlicensed by the HTA where an appropriate TPA is not in place) to be a Serious Adverse Event (SAE) as it could have implications for other patients or donors because of shared practices, services, supplies or donors.

The HTA also considers procurement of cord blood by untrained personnel, whether undertaken unlawfully or under the authority of an HTA licence or TPA, to be an SAE for the same reason as described in paragraph 7 above.

The HTA requires all SAEs to be reported via the Serious Adverse Events and Reactions (SAEARs) reporting mechanism, available on the HTA’s website.

Receipt of cord blood into an HTA-licensed establishment

DIs must ensure that robust receipt procedures are in place to verify that cord blood has been lawfully procured by a person who is trained to the DI’s satisfaction. DIs should refer to paragraphs 116-224 of the Guide to Quality and Safety Assurance of Human Tissues and Cells for Patient Treatments as implemented by Directions 001/2021 for the HTA’s requirements for tissue and cell receipt.

Cord blood procurement scenarios
Serious adverse events (SAEs) reporting
Position Statement
Common questions about regulations and cord blood procurement
Cord blood procurement specific scenarios